NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 01:30PM ET
4.58
Dollar change
+0.09
Percentage change
2.00
%
Index- P/E- EPS (ttm)-10.78 Insider Own14.84% Shs Outstand7.31M Perf Week7.26%
Market Cap33.46M Forward P/E- EPS next Y-6.49 Insider Trans-0.08% Shs Float6.22M Perf Month4.33%
Enterprise Value-66.79M PEG- EPS next Q-2.23 Inst Own55.49% Short Float0.85% Perf Quarter-0.43%
Income-78.63M P/S- EPS this Y31.54% Inst Trans4.26% Short Ratio1.52 Perf Half Y-32.84%
Sales0.00M P/B0.32 EPS next Y17.48% ROA-48.48% Short Interest0.05M Perf YTD-31.85%
Book/sh14.11 P/C0.29 EPS next 5Y18.69% ROE-57.78% 52W High9.18 -50.11% Perf Year-21.52%
Cash/sh15.65 P/FCF- EPS past 3/5Y-3.52% 8.98% ROIC-72.61% 52W Low3.62 26.52% Perf 3Y-94.48%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.64% 6.79% Perf 5Y-91.53%
Dividend TTM- EV/Sales- EPS Y/Y TTM22.70% Oper. Margin- ATR (14)0.30 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.09 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)54.77 Recom1.80
Dividend Gr. 3/5Y- - Current Ratio7.09 EPS Q/Q23.83% SMA203.00% Beta0.66 Target Price12.50
Payout- Debt/Eq0.14 Sales Q/Q- SMA506.09% Rel Volume0.65 Prev Close4.49
Employees55 LT Debt/Eq0.05 EarningsMay 13 AMC SMA200-22.64% Avg Volume34.69K Price4.58
IPOJun 21, 2018 Option/ShortYes / Yes EPS/Sales Surpr.12.86% - Trades Volume22,529 Change2.00%
Date Action Analyst Rating Change Price Target Change
Aug-11-23Downgrade Wells Fargo Overweight → Equal Weight $4
Mar-16-23Downgrade William Blair Outperform → Mkt Perform
Dec-08-21Initiated Wells Fargo Overweight $19
Jul-16-18Initiated William Blair Outperform
Jul-16-18Initiated Wells Fargo Outperform $30
Jul-16-18Initiated Jefferies Buy
May-28-25 04:01PM
May-27-25 12:00PM
May-13-25 04:01PM
Mar-25-25 06:54PM
07:30AM
08:00AM Loading…
Mar-24-25 08:00AM
Feb-18-25 04:01PM
Nov-13-24 12:30PM
Nov-12-24 04:01PM
Oct-28-24 08:30AM
Oct-18-24 11:02AM
Oct-17-24 01:37PM
08:35AM
08:30AM
Oct-15-24 12:00PM
08:30AM Loading…
Oct-10-24 08:30AM
Oct-08-24 07:04PM
Oct-07-24 08:50AM
04:52AM
Oct-04-24 05:00PM
Oct-01-24 04:52AM
Sep-30-24 08:30AM
Sep-04-24 04:01PM
Aug-14-24 11:13AM
Aug-13-24 04:02PM
Jul-10-24 04:01PM
Jun-07-24 05:59PM
May-29-24 04:01PM
May-09-24 10:57PM
04:01PM
04:05PM Loading…
May-06-24 04:05PM
Apr-08-24 05:38PM
04:01PM
Mar-27-24 04:30PM
Mar-16-24 06:56AM
Mar-14-24 09:54PM
04:01PM
Mar-08-24 04:05PM
Feb-28-24 04:01PM
Feb-26-24 06:30PM
Feb-25-24 02:12PM
Feb-02-24 05:37AM
Dec-18-23 08:51AM
Nov-21-23 04:01PM
Nov-13-23 04:01PM
Nov-03-23 04:03PM
Oct-24-23 12:30PM
Oct-23-23 10:08AM
Oct-09-23 05:56PM
Oct-04-23 09:32AM
Oct-03-23 04:10PM
Sep-20-23 06:30PM
Aug-31-23 04:01PM
Aug-10-23 04:01PM
Aug-04-23 04:03PM
Jul-07-23 04:01PM
Jun-09-23 04:01PM
May-31-23 07:00AM
May-11-23 04:01PM
Apr-05-23 04:01PM
Mar-14-23 04:01PM
Mar-13-23 07:00AM
Mar-06-23 07:00AM
Mar-03-23 06:17PM
Mar-01-23 04:01PM
Feb-06-23 04:01PM
11:44AM
Jan-26-23 06:44AM
Jan-13-23 04:01PM
Jan-06-23 07:04AM
Jan-04-23 04:01PM
Dec-07-22 04:01PM
Nov-14-22 07:00AM
Nov-11-22 04:01PM
Nov-10-22 04:01PM
Nov-09-22 04:01PM
Nov-03-22 10:00AM
Oct-14-22 07:00AM
Oct-06-22 04:01PM
Oct-03-22 04:01PM
Sep-29-22 04:05PM
Sep-02-22 04:30PM
Sep-01-22 07:00AM
Aug-30-22 12:10PM
Aug-11-22 04:01PM
Aug-03-22 04:30PM
Jul-18-22 09:55AM
Jul-11-22 04:30PM
Jul-08-22 02:42PM
Jul-07-22 04:30PM
Jul-06-22 04:30PM
Jun-30-22 01:08PM
09:55AM
Jun-28-22 03:57PM
11:58AM
10:23AM
09:58AM
Jun-27-22 09:31PM
04:01PM
11:46AM
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 19, 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chiang Pichi LuoSVP, Corporate ControllerJul 02 '25Sale4.282641,1302,711Jul 03 04:15 PM
Schiller Mark C.Chief Operating OfficerJul 02 '25Sale4.285612,4012,739Jul 03 04:15 PM